All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-03-28T10:36:38.000Z

EHA-SWG 2017 | Rare Lymphomas: Treatment of WM

Mar 28, 2017
Share:

Bookmark this article

On March 11th, at the EHA-SWG Rare Lymphomas Scientific Meeting 2017 in Barcelona, Spain, Marie José Kersten chaired a scientific session on ‘Waldenström’s Macroglobulinemia’. The second presentation of this session was originally intended to be presented by Meletios Dimopoulos, but was presented by Marie José Kersten on the topic of ‘Treatment of WM’. Below are the key highlights from this presentation:

  • The session began with an overview of WM and when to initiate therapy

  • Options for treating WM have expanded greatly in the last decade and now include proteasome inhibitors, rituximab, alkylating agents, monoclonal antibodies, etc.
  • Rituximab-based regimens have the best outcome for first-line WM patients
  • Dexamethasone, rituximab, cyclophosphamide treatment was shown to have 83% ORR. But with high IgM flare rate (32% pts; 11% pts >25% IgM increase)

  • A summary of data for proteasome inhibitors and combination therapy was presented, and it was reported that no pts needed plasmapheresis due to IgM flare:

  • Rituximab maintenance was shown to result in significantly higher PFS and OS in patients with WM however, this data was from a retrospective analysis

  • Novel drug targets:

  • Ibrutinib has been shown to be effective in previously treated WM with a 68.1% EFS (95% CI), 90% OS (95% CI) with a median follow-up of 37 months

  • In conclusion, rituximab-based therapy is recommended in first-line patients, but evidence is less clear for relapsed WM patients

  1. Dimopoulos M. (Kersten M.J.) Treatment of WM. 2017 Mar 11. EHA-SWG Rare Lymphomas. Barcelona, Spain.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox